Anna Bruckner

Study of the Safety, Tolerability, and Efficacy of an iPS Cell-Based Therapy for Recessive Dystrophic Epidermolysis Bullosa Delivered with a Spray on Skin Device

National Institute of Arthritis and Musculoskeletal and Skin Diseases · UG3

PI · $538.2K · University of Colorado Denver

JAK Inhibition in Down Syndrome

National Institute of Arthritis and Musculoskeletal and Skin Diseases · R33

PI · $2.8M · University of Colorado Denver

Phase 2 Study of Sildenafil for the Treatment of Lymphatic Malformations

Food and Drug Administration · R01

PI · $882K · Stanford University

Pediatric Dermatology Research Alliance (PeDRA) Annual Conference

National Institute of Arthritis and Musculoskeletal and Skin Diseases · R13

Contact PI · $90K · University of Colorado Denver

A Pilot Study Exploring the Efficacy and Safety of Topical Oxybutynin 3% Gel for Primary Focal Hyperhidrosis in Adolescents and Young Adults

Principal investigator · Completed

University of Colorado, Denver

A Long-Term Safety Follow-up Registry for Patients Who Received Treatment With Prademagene Zamikeracel for Recessive Dystrophic Epidermolysis Bullosa (RDEB) in the Post-Marketing Setting

Site PI · Recruiting

Abeona Therapeutics, Inc